As of 2025-11-17, the EV/EBITDA ratio of Xlife Sciences AG (XLS.SW) is -48.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. XLS.SW's latest enterprise value is 160.01 mil CHF. XLS.SW's TTM EBITDA according to its financial statements is -3.31 mil CHF. Dividing these 2 quantities gives us the above XLS.SW EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.5x - 24.6x | 18.8x |
| Forward P/E multiples | 11.2x - 12.7x | 11.4x |
| Fair Price | (19.13) - (17.53) | (18.90) |
| Upside | -209.3% - -200.2% | -208.0% |
| Date | EV/EBITDA |
| 2025-11-14 | -48.31 |
| 2025-11-13 | -47.43 |
| 2025-11-12 | -48.31 |
| 2025-11-11 | -50.48 |
| 2025-11-10 | -49.87 |
| 2025-11-07 | -49.18 |
| 2025-11-06 | -49.61 |
| 2025-11-05 | -52.57 |
| 2025-11-04 | -52.66 |
| 2025-11-03 | -52.66 |
| 2025-10-31 | -51.79 |
| 2025-10-30 | -52.66 |
| 2025-10-29 | -52.66 |
| 2025-10-28 | -51.79 |
| 2025-10-27 | -52.66 |
| 2025-10-24 | -52.66 |
| 2025-10-23 | -53.18 |
| 2025-10-22 | -53.53 |
| 2025-10-21 | -53.36 |
| 2025-10-20 | -54.05 |
| 2025-10-17 | -53.53 |
| 2025-10-16 | -54.23 |
| 2025-10-15 | -52.49 |
| 2025-10-14 | -52.49 |
| 2025-10-13 | -52.66 |
| 2025-10-10 | -52.31 |
| 2025-10-09 | -53.88 |
| 2025-10-08 | -54.05 |
| 2025-10-07 | -53.01 |
| 2025-10-06 | -53.01 |
| 2025-10-03 | -53.01 |
| 2025-10-02 | -50.92 |
| 2025-10-01 | -54.23 |
| 2025-09-30 | -53.53 |
| 2025-09-29 | -52.66 |
| 2025-09-26 | -52.66 |
| 2025-09-25 | -54.40 |
| 2025-09-24 | -54.23 |
| 2025-09-23 | -51.96 |
| 2025-09-22 | -52.49 |
| 2025-09-19 | -50.92 |
| 2025-09-18 | -52.83 |
| 2025-09-17 | -52.83 |
| 2025-09-16 | -52.14 |
| 2025-09-15 | -52.66 |
| 2025-09-12 | -55.10 |
| 2025-09-11 | -53.70 |
| 2025-09-10 | -55.27 |
| 2025-09-09 | -54.40 |
| 2025-09-08 | -55.27 |